Curasight announces acceleration of therapeutic strategy to strengthen position as a radiopharmaceutical theranostic company

Coming Phase I/IIa basket trial planned to include five select cancer indicationsStudy will apply Curasight's uPAR theranostic platform approach combining diagnosis (uTRACE®) and therapy (uTREAT®)First patients expected to be dosed in the beginning of 2025 with expected first efficacy data in 2025.View original content:https://www.prnewswire.co.uk/news-releases/curasight-announces-acceleration-of-therapeutic-strategy-to-strengthen-position-as-a-radiopharmaceutical-theranostic-company-302060399.html

en | boerse | 67941638 |